SUVENPHAR.BOSUVENPHAR.BOBSE
Loading
EBITDA Over TimeStable
Percentile Rank17
3Y CAGR-11.2%
5Y CAGR+1.2%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
-11.2%/yr
Annual compound
5Y CAGR
+1.2%/yr
Recent deceleration
Percentile
P17
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive declineStable
PeriodValueYoY Change
2025$4.06B-0.8%
2024$4.09B-28.6%
2023$5.73B-1.2%
2022$5.79B+31.5%
2021$4.41B+15.5%
2020$3.82B-8.6%
2019$4.18B-